KDM6B and neoplasm: Inhibition of the histone demethylases KDM6A and KDM6B by a pharmacological inhibitor, GSKJ4, increased global H3K27me3 in K27M-mutant brainstem gliomas, leading to reduced tumor growth, improved survival, and sensitized tumor cells to radiation therapy in preclinical models (233).